Neurochemistry and neuropharmacology of schizophrenia
Author(s)
Bibliographic Information
Neurochemistry and neuropharmacology of schizophrenia
（Handbook of schizophrenia / edited by H.A. Nasrallah, v. 2）
Elsevier , Sole distributors for the USA and Canada, Elsevier Science Pub. Co., 1987
Available at / 22 libraries
-
No Libraries matched.
- Remove all filters.
Note
Includes bibliographies and index
Description and Table of Contents
Description
This volume brings together a wealth of data on the neurochemistry and neuropharmacology of schizophrenia. It provides investigators of the etiology of schizophrenia with a basis to formulate future directions. A major portion of the book is devoted to an analysis of the dopamine neurotransmitter system in recognition of the fact that it may represent the most likely site for neurochemical abnormalities to be found in schizophrenia. Developments in the pharmacologic treatment of schizophrenia are dealt with in six authoritative reviews and the advances detailed therein may set the stage for a second generation of improved antipsychotic medications.
Table of Contents
Introduction (F.A. Henn, Stony Brook, NY, and L.E. DeLisi, Bethesda, MD). 1. A historical perspective to the chemistry and pharmacological treatment of schizophrenia (A. Carlsson, Goteborg, Sweden). 2. Two syndromes of schizophrenia as one pole of the continuum of psychosis: a conflict of the nature of the pathogen and its genomic locus (T.J. Crow, Harrow, UK). 3. Neuroanatomical localization of dopamine in the brain and spinal cord (O. Lindvall and A. Bjorklund, Lund, Sweden). 4. Pharmacology of central dopaminergic neurons (M.E. Wolf, Detroit, MI, A.Y. Deutch and R.H. Roth, New Haven, CT). 5. Central dopaminergic systems: neurophysiology and electrophysiological pharmacology (B.S. Bunney and S.R. Sesack, New Haven, CT). 6. Neuroleptic treatment of schizophrenia (J.M. Kane, Glen Oaks, NY). 7. New pharmacological treatments for schizophrenia (J.M. Cott, and N.M. Kurtz Wallingsord, CT). 8. Norepinephrine metabolism in schizophrenia (C.R. Lake, Bethesda, MD, J. Kleinman, Washington, DC, M.S. Kafka, Rockville, MD, G. Ko, Seattle, WA, S. Smith Moore, Bethesda, MD, and M. Ziegler, San Diego, CA). 9. Indoleamines and schizophrenia (S.M. Stahl, Harlow, UK, and K. Wets, London, UK). 10. The role of neuroleptics in schizophrenia (C.B. Nemeroff and G. Bissette, Durham, NC). 11. Phospholipids and prostaglandins in schizophrenia (D. Brody, A. Wolkin and J. Rotrosen, New York, NY). 12. The neuroendocrinology of schizophrenia (P. Powchik, B.M. Davis and K.L. Davis, Bronx, NY). 13. Endogenous hallucinogens and other behavioral modifying factors in schizophrenia (L.E. DeLisi and R.J. Wyatt, Bethesda, MD). 14. Pharmacological models of schizophrenia (B. Angrist, New York, NY). 15. Tardive dyskinesia and schizophrenic burnout: the possible involvement of cytotoxic free radicals (J.L. Cadet, J.B. Lohr and D.V. Jeste, Washington, DC). 16. Neurological disorders and schizophrenia (M. Trimble and D. Rogers, London, UK). 17. Genetic aspects of the biology of schizophrenia (L.R. Goldin, L.E. DeLisi, and E.S. Gershon, Bethesda, MD). 18. Conclusion (F.A. Henn, Stony Brook, NY and L.E. DeLisi, Bethesda, MD). Subject index.
by "Nielsen BookData"